CPAP for sleep apnoea does not enhance asthma control, but improves daytime sleepiness, QoL
There appears to be a high prevalence of obstructive sleep apnoea syndrome (OSAS) among patients with asthma and snoring, reports a study. Continuous positive airway pressure (CPAP) treatment for 3 months does not improve asthma control but enhances daytime sleepiness, quality of life and vitality.
A total of 145 patients were recruited, of which 122 underwent sleep study with 41 (33.6 percent) having apnoea–hypopnoea index (AHI) ≥10/h. The following characteristics were observed in patients with significant OSAS: higher body mass index (27.4 vs 25.1 kg/m2; p=0.016), bigger neck circumference (36.6 vs 34.8 cm; p=0.006) and lower minimum SaO2 (80.7 vs 87.2 percent; p<0.001).
Intention-to-treat analysis among 37 patients with AHI ≥10/h (CPAP group [n=17] vs control group [n=20]) showed no significant between-group difference in Asthma Control Test score (3.2 vs 2.4; p=0.568), but the CPAP group had a greater improvement in Epworth Sleepiness Scale (–3.0 vs 0.5; p=0.014), Asthma Quality of Life Questionnaire (0.6 vs 0.02; p=0.022) and vitality domain in the SF-36 questionnaire (14.7 vs 0.3; p=0.012) after 3 months.
This study examined asthma control, airway responsiveness, daytime sleepiness and health status at baseline and 3 months after CPAP therapy among asthma patients with nocturnal symptoms and OSAS.
Using Embletta portable diagnostic system, patients with nocturnal asthma symptoms despite receiving at lease moderate-dose inhaled corticosteroid and long-acting bronchodilators underwent a home sleep study. Those with significant OSAS were randomly assigned to receive either CPAP or conservative treatment for 3 months.
“Unrecognized OSAS may lead to poor asthma control despite optimal therapy,” the authors said.